Best Peptides for Weight Loss: What the Research Shows

The peptide space has produced some of the most compelling weight management research in recent history. From GLP-1 receptor agonists to growth hormone secretagogues, several compounds have demonstrated significant fat loss effects in controlled studies. Here's what the evidence actually shows.

1. Semaglutide — The Benchmark

Semaglutide remains the most clinically studied peptide for weight loss. As a GLP-1 receptor agonist, it works by slowing gastric emptying, reducing appetite signals in the hypothalamus, and improving insulin sensitivity. The STEP trials showed an average of 15–17% body weight reduction over 68 weeks — results previously unseen outside of bariatric surgery.

• 15–17% average body weight reduction in STEP clinical trials
• Significant reduction in waist circumference and visceral fat
• Improved fasting glucose and HbA1c
• Cardiovascular risk reduction in SELECT trial

2. CJC-1295 / Ipamorelin — Indirect Fat Loss via GH

Growth hormone has well-documented lipolytic effects — it directly stimulates the breakdown of stored fat (lipolysis) and inhibits fat storage. CJC-1295 paired with Ipamorelin produces sustained, physiological GH elevation that supports fat metabolism, particularly visceral and subcutaneous adipose tissue reduction.

• GH-mediated lipolysis — direct fat cell breakdown
• Preferential loss of visceral fat in animal models
• Preservation of lean muscle mass during caloric restriction
• Improved insulin sensitivity over time

3. BPC-157 — Supporting the Metabolic Environment

While BPC-157 is not a direct fat loss compound, its role in gut healing and metabolic regulation deserves mention in weight management research. Gut microbiome health and intestinal barrier integrity are increasingly recognized as critical factors in metabolic health and body composition. BPC-157's documented effects on gut mucosal healing may support an optimal metabolic environment.

Stacking Considerations

Research contexts often combine compounds with complementary mechanisms. A GLP-1 agonist like semaglutide addresses appetite and insulin signaling, while a GH secretagogue stack addresses direct lipolysis and muscle preservation. These are distinct pathways that can theoretically be studied in combination — though this requires careful protocol design.

This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.